Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion Granted US Patent for Lung Cancer Biomarkers

Premium

Vermillion said this week it has received a US patent covering serum protein biomarkers for lung cancer.

The patent, No. 8,014,952, entitled "Serum Biomarkers in Lung Cancer," describes 50 protein biomarkers that can be used to distinguish between patients with and without lung cancer and to determine the particular type of lung cancer.

"This patent highlights ongoing progress in expanding our intellectual property portfolio," Vermillion CEO Gail Page said in a statement. "Beyond our core focus areas of ovarian cancer and peripheral artery disease, we now have patents in lung cancer, breast cancer, and Alzheimer's disease. It is our goal to explore business opportunities to leverage this growing and valuable asset."

In addition to Vermillion, Hong Kong's Queen Elizabeth Hospital is listed as an assignee on the patent.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.